High Plasma d-dimer Level is Associated with Decreased Survival in Patients with Lung Cancer

Clinical Oncology

Volumn 19, Issue 7, 2007, Pages 494-498

  Altiay, G ^a   Ciftci, A ^a   Demir, M ^a   Kocak, Z ^a   Sut, N ^a   Tabakoglu, E ^a   Hatipoglu, O N ^a   Caglar, T ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

d dimer; lung cancer; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; D DIMER; DOCETAXEL; ETOPOSIDE; FIBRINOGEN; GEMCITABINE; LACTATE DEHYDROGENASE; PACLITAXEL; PROTHROMBIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HUMAN; KARNOFSKY PERFORMANCE STATUS; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 34547540188     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.04.002     Document Type: Article

References (22)

1. Goad K.E., and Gralnick H.R. Coagulation disorders in cancer. Hematol Oncol Clin North Am 10 (1996) 457-484
2. Buccheri G., Torchio P., and Ferringo D. Plasma levels of D-dimer in lung cancer. Cancer 97 (2003) 3044-3052
3. Blackwell K., Haroon Z., Broadwater G., et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 18 (2000) 600-608
4. Oya M., Akiyama Y., Okuyama T., and Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumour stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 31 (2001) 388-394
5. Taguchi O., Gabazza E.C., Yasui H., Kobayashi T., Yoshida M., and Kobayashi H. Prognostic significance of plasma D-dimer levels in patient with lung cancer. Thorax 52 (1997) 563-565
6. Gabazza E.C., Taguchi O., Yamakami T., Machishi M., Ibata H., and Suzuki S. Evaluating the prethrombotic state in lung cancer using molecular markers. Chest 103 (1993) 196-200
7. Unsal E., Atalay F., Atikcan S., and Yi{dotless}lmaz A. Prognostic significance of haemostatic parameters in patients with lung cancer. Respir Med 98 (2004) 93-98
8. Antoniou D., Pavlakou G., Stathopoulos G.P., et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer 53 (2006) 205-210
9. Rak J., Milsom C., May L., Klement P., and Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 32 (2006) 54-70
10. Bootle-Wilbraham C.A., Tazzyman S., Marshall J.M., and Lewis C.E. Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res 60 (2000) 4719-4724
11. Thompson W.D., Smith E.B., Stirk C.M., Marshall F.I., Stout A.J., and Kocchar A. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J Pathol 168 (1992) 47-53
12. Bick R.L. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 18 (1992) 353-372
13. Dvorak H.F. Tumours: wounds that do not heal. Similarities between tumour stroma generation and wound healing. N Engl J Med 315 (1986) 1650-1659
14. Buccheri G., Ferrigno D., Ginardi C., and Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer 33 (1997) 50-55
15. Sallah S., Husain A., Sigounas V., et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulant therapy. Clin Cancer Res 10 (2004) 7238-7243
16. Mountain C.F. Revisions in international system for staging lung cancer. Chest 111 (1997) 1710-1717
17. Gasic G.J., Tuszynski G.P., and Gorelik E. Interaction of the haemostatic and immune systems in the metastatic spread of tumour cells. Int Rev Exp Pathol 29 (1986) 173-212
18. Seitz R., Rappe N., Kraus M., et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 4 (1993) 249-254
19. Pavey S.J., Hawson G.A., and Marsh N.A. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis 12 (2001) 51-58
20. Zacharski L.R., Henderson W.G., Rickles F.R., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study 75. Cancer 53 (1984) 2046-2052
21. Altinbas M., Coskun H.S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 (2004) 1266-1271
22. Klerk C.P., Smorenburg S.M., Otten H.M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 (2005) 2130-2135